GSK expands into Pakistan
This article was originally published in The Tan Sheet
Executive Summary
The U.K. firm gains more than 30 pharmaceutical brands, including antibiotics, vitamins and dermatology products, in its purchase of Bristol-Myers Squibb Pakistan, GlaxoSmithKline announces Dec. 22. The $36.5 million acquisition "reinforces our commitment to Pakistan" and broadens GSK's product portfolio, says Abbas Hussain, president of emerging markets for GSK. The company says BMSP's 2007 sales were about $19 million and Pakistan's total pharmaceutical market is $1.2 billion. GSK's goal is to introduce old products in new places and coordinate its Rx and OTC segments in emerging markets (1"The Tan Sheet" Oct. 27, 2008, p. 14)
You may also be interested in...
GSK Counts On China, Product Innovation To Boost Consumer Product Sales
GlaxoSmithKline recently launched its Sensodyne toothpaste line in China, its first new product there in more than 10 years
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.